This is an aggregated industry headline. Read the full story at Drug Channels →
The IRA Fixed One Medicare Part D Distortion-But Patients Now Face New Tradeoffs
By Bryce Platt, PharmD For years, Medicare Part D plans often preferred high-list/high-rebate branded multiple sclerosis (MS) drugs over lower-cost generics. That was rational behavior inside an irrational system. The Inflation Reduction Act (IRA) offers one example of how incentives can change beha
By Drug Channels
· Jun 16, 2026
· via Drug Channels
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Shionogi's "Got the Call, Make the Call" campaign for COVID antiviral Xocova kicks off with a TV ad depicting …
The WeekFierceBiotech ↗
Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sle…
The WeekBriefing
FDA’s July 30 notice sets FY 2027 PDUFA fees below FY 2026 levels for clinical-data applications, non-clinical…